4-Methylcyclohexanemethanol Acute Toxicity to Daphnia and Its Effects on General Esterase and Glutathione S-Transferase Activity in Fathead Minnows

In 2014, 10,000 gallons of crude MCHM spilled into the Elk River in West Virginia. Due to a paucity of information about the toxicity of this chemical prior to the spill, our research aimed to verify the published 48-h EC50 for Daphnia magna (Daphnia) examine the effects of MCHM on two enzyme detoxification systems, general esterase and glutathione S-transferase, in Pimephales promelas (Fathead Minnow). We used pure MCHM instead of the crude form used in Eastman’s toxicity tests because the composition of crude MCHM is variable. The EC50 we obtained for pure MCHM did not differ significantly from the EC50 provided by Eastman for the crude form. We exposed Fathead Minnows to sublethal environmentally-relevant concentrations of MCHM for 96 h prior to performing the enzyme assays. The experimental groups in these assays did not show significant difference from control groups. Although our results add to the toxicity information, there is still a concerning deficit in chronic toxicity testing because of possible prolonged human exposure following the spill

Extension of Zero Voltage Switching Capability for CLLC Resonant Converter

TheCLLC resonant converter has been widely used to obtaina high power conversion efficiency with sinusoidal current waveforms and a soft switching capability. However, it has a limited voltage gain range according to the input voltage variation. The current-fed structure canbe one solution to extend the voltage gain range for the wide input voltage variation, butit has a limited zero voltage switching (ZVS) range. In this paper, the current-fed CLLC resonant converter with additional inductance is proposed to extend the ZVS range. The operational principle is analyzed to design the additional inductance for obtaining the extended ZVS range. The design methodology of the additional inductance is proposed to maximize the ZVS capability for the entire load range. The performance of the proposed method is verified with a 20 W prototype converter

Design Methodology of Tightly Regulated Dual-Output LLC Resonant Converter Using PFM-APWM Hybrid Control Method

A dual-output LLC resonant converter using pulse frequency modulation (PFM) and asymmetrical pulse width modulation (APWM) can achieve tight output voltage regulation, high power density, and high cost-effectiveness. However, an improper resonant tank design cannot achieve tight cross regulation of the dual-output channels at the worst-case load conditions. In addition, proper magnetizing inductance is required to achieve zero voltage switching (ZVS) of the power MOSFETs in the LLC resonant converter. In this paper, voltage gain of modulation methods and steady state operations are analyzed to implement the hybrid control method. In addition, the operation of the hybrid control algorithm is analyzed to achieve tight cross regulation performance. From this analysis, the design methodology of the resonant tank and the magnetizing inductance are proposed to compensate the output error of both outputs and to achieve ZVS over the entire load range. The cross regulation performance is verified with simulation and experimental results using a 190 W prototype converter

Critical current densities and flux creep rates in near optimally doped BaFe2-xRuxAs2 (x≈0.7) single crystals

We present an investigation of the critical current densities Jc and flux creep rates in a near optimally doped BaFe2-xRuxAs2 (x≈0.7) single crystal by (measuring magnetization). The superconducting critical temperature is 18 K. The in-field dependences of the critical current density Jc are due to a mixed pinning scenario produced mainly by large precipitates and a less significant contribution of random disorder. Furthermore, a Maley analysis in the regime dominated by strong pinning centers (μ0H=0.1 T) is well described through a glassy exponent μ=1.9 and a collective pinning energy (U0) smaller than 100 K.Fil: Haberkorn, Nestor Fabian. Comisión Nacional de Energía Atómica. Gerencia del Área de Energía Nuclear. Instituto Balseiro; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Eom, Man Jin. Pohang University of Science and Technology; Corea del SurFil: You, Jung Sang. Pohang University of Science and Technology; Corea del SurFil: Kim, Jeehoon. Pohang University of Science and Technology; Corea del SurFil: Kim, Jun Sung. Pohang University of Science and Technology; Corea del Su

Enhanced Switching Pattern to Improve Cell Balancing Performance in Active Cell Balancing Circuit using Multi-winding Transformer

Cell balancing performance is an important factor in determining the operational efficiency of the active cell balancing circuit. Thus, this study approached this need by developing an enhanced switching pattern. The circuit is designed to transfer energy between arbitrary source and target cells. It has been operated in flyback and buck-boost modes according to the position of the source and target cells. In this circuit, the coupling coefficient of the transformer considerably affects the balancing performance of the flyback operation. The energy transferred to the non-target cell is increased by the low-coupling coefficient due to the leakage inductance. Therefore, the high energy transfer ratio cannot be achieved using conventional switching patterns. In this paper, a new flyback switching pattern is proposed, which can minimize the effect of the coupling coefficient in the cell balancing operation. The proposed switching pattern uses the cells which do not participate in the balancing process to control the voltage applied to each winding, which results in a high energy transfer ratio irrespective of the coupling coefficient. In addition, an enhanced operating method has been proposed to improve the cell balancing speed by reducing the energy transfer path in specific cell conditions. The performance of the proposed switching pattern was verified in a 15 W cell balancing circuit

Longitudinal Patterns in Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention in the Non-Vitamin K Oral Anticoagulant Era:A Nationwide Population-Based Study

We investigated whether longitudinal patterns in antithrombotic therapy have changed after the introduction of non-vitamin K oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI). Using a claims database of the Korean AF population who underwent PCI between 2012 and 2016 (n = 18,691), we analyzed prescription records of oral anticoagulants (OACs) and antiplatelets at 3-month intervals over 2 years after PCI. The study population was stratified (pre-NOAC, transition, and NOAC era) using time-periods of NOAC introduction in Korea and an expansion of reimbursement for NOAC in AF as indicators. The overall rates of OAC were low at baseline (24.9%, 26.9%, and 35.2% in pre-NOAC, transition, and NOAC era, respectively), contrary to high rates of dual antiplatelet therapy (DAPT) (73.3%, 71.4%, and 63.6%). However, OAC prescription rates were increased at 1-year (18.5%, 22.5%, and 31.6%), and 2-year follow-up (17.8%, 24.2%, and 31.8%) from pre-NOAC to NOAC era. In NOAC era, 63.5% of baseline OAC prescriptions comprised NOAC, of which 96.4% included triple therapy with DAPT. Over 2 years, we observed increasing rates of double therapy with a single antiplatelet (18.3% and 20.0% at 1- and 2-year follow-up) and OAC monotherapy (2.7% and 8.9% at 1- and 2-year follow-up)

Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease

OBJECTIVES: To compare the net clinical benefit of oral anticoagulant (OAC) monotherapy to OAC plus single antiplatelet therapy (SAPT) in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) at 1- and 3-year after percutaneous coronary intervention (PCI). BACKGROUND: It has not been studied whether the net clinical benefit of the antithrombotic treatment options differs depending on the elapsed time from the index PCI. METHODS: Using the Korean nationwide claims database, we included AF patients who underwent PCI from 2009 to 2019 and constructed two cohorts: 1- and 3-year after PCI. In each cohort, the baseline characteristics of two groups were balanced using propensity score weighting. Ischemic stroke, myocardial infarction, major bleeding, and composite clinical outcomes were analyzed. RESULTS: Among patients with 1-year after PCI, OAC monotherapy (n = 678), and OAC plus SAPT (n = 3,159) showed comparable results for all clinical outcomes. In patients with 3-year after PCI, OAC monotherapy (n = 1,038) and OAC plus SAPT (n = 2,128) showed comparable results for ischemic stroke and myocardial infarction, but OAC monotherapy was associated with a lower risk of composite clinical outcomes (HR 0.762, 95% CI 0.607–0.950), mainly driven by the reduction of major bleeding risk (HR 0.498, 95% CI 0.345–0.701). CONCLUSION: Oral anticoagulant monotherapy may be a comparable choice for patients with AF and stable CAD compared to OAC plus SAPT. In patients with stable CAD more than 3-year after index PCI, OAC monotherapy would be a better choice, being associated with less major bleeding and a positive net clinical benefit

Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention

BACKGROUND AND OBJECTIVE: Most Asian patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) receive only dual antiplatelet therapy (DAPT) without oral anticoagulants (vitamin K antagonists [VKA] or non-VKA oral anticoagulants [NOAC]). However, it has not been fully investigated whether the DAPT results in better clinical outcomes in the early period after PCI than the standard triple therapy with VKA or NOAC. METHODS: We analyzed the claims records of 11,039 Korean AF population who had PCI between 2013 and 2018. Patients were categorized according to the post-PCI antithrombotic therapy as VKA-based triple therapy (VKA-TT), NOAC-based triple therapy (NOAC-TT), and DAPT groups. After baseline adjustment using inverse probability weighting, we compared the risks of ischemic endpoints (ischemic stroke, myocardial infarction, and all-cause mortality) and major bleeding at 3 months post-PCI. RESULTS: Ischemic stroke, MI, and all-cause mortality occurred in 105, 423, and 379 patients, respectively, and 138 patients experienced major bleeding. The DAPT group was associated with a lower risk of ischemic stroke and major bleeding (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.37–0.84) compared to the VKA-TT group, despite no significant differences in the risks of MI and all-cause mortality. In contrast, the DAPT group demonstrated no significant difference in the risks for ischemic endpoints compared to the NOAC-TT group. Additionally, the DAPT group had a numerically lower risk of major bleeding than the NOAC-TT group but this was not statistically significant (HR 0.69, 95% CI 0.45–1.07). CONCLUSIONS: An outcome benefit of DAPT was observed in the early period after PCI compared to the VKA-TT, but not against NOAC-TT users among the Asian AF population. Given the potential long-term benefits of NOACs, greater efforts should be made to increase compliance in clinical practice with proper combination therapy with NOAC after PCI